Browsing Tag
oncology biotech
9 posts
Can C4 Therapeutics (CCCC) balance dilution and growth with its $400m shelf plan?
C4 Therapeutics files $400M shelf to support oncology trials. Find out what this means for investors and the company’s future strategy.
Radiopharm Theranostics (ASX: RAD) begins third cohort in PD-L1 trial—could 177Lu-RAD204 be a game-changer?
Radiopharm Theranostics moves to third cohort in PD-L1 trial with 90mCi dose approval. Explore what this means for its radiopharmaceutical ambitions.
Investors eye Plus Therapeutics after promising ReSPECT-LM results and FDA fast-track push for REYOBIQ in brain metastases
See how Plus Therapeutics’ REYOBIQ delivered >75 percent benefit and no toxicity in its ReSPECT-LM trial—discover what this means for CNS cancer treatment and investors.
Breakthrough results: Intensity Therapeutics’ INT230-6 delivers strong survival and immune response in phase 1/2 cancer trial
Find out how Intensity Therapeutics’ INT230-6 achieved 11.9-month survival and immune activation in metastatic cancer—read what this means for biotech investors.
Avacta Group PLC (AIM: AVCT) shares rise on dual payload breakthrough: Is a clinical re-rating next?
Avacta shares rise after unveiling dual payload cancer therapy at AACR-NCI-EORTC. Can the stock sustain momentum as it approaches clinical milestones?
Can Avacta’s peptide drug conjugates rival ADCs? The next chapter in targeted cancer delivery
Avacta’s peptide drug conjugates could change how we deliver cancer drugs. Find out how they compare to ADCs and what’s next for the UK biotech’s platform.
Avacta completes Coris sale in final diagnostics exit: Is its precision oncology pivot ready for prime time?
Avacta completes sale of Coris Bioconcept to focus solely on oncology. Find out what this pivot means for its stock, strategy, and pre|CISION® pipeline.
Moleculin Biotech (NASDAQ: MBRX) launches stock offering to support pivotal cancer drug trial and IND filings
Moleculin Biotech to raise $5.9M to fund its Phase 3 trial for Annamycin and expand oncology pipeline. Explore what this means for AML treatment and investors.
Senti Biosciences gets FDA orphan drug status for SENTI-202 in relapsed AML treatment
Senti Biosciences earns FDA orphan drug designation for SENTI-202 in AML. Find out how this logic-gated CAR-NK therapy could reshape leukemia treatment.